The appointment of two dedicated business development directors, Michael Nyman and Josephine Crespo, will enable the company to better serve its strategically important and growing client base in North America.
Michael Nyman, based in San Diego, has held a number of international business development roles, most recently with Syngene.
Michael is a chemist by training and spent the first 20 years of his career in various industrial chemistry roles encompassing radiochemistry, pilot plant manufacture, automated parallel synthesis and medicinal chemistry at companies including COR Therapeutics, Bristol Myers Squibb and X-Ceptor/Exelixis.
Josephine Crespo will be based in Boston for East coast business. Josephine trained as a biologist and has more than 17 years of experience of selling specialist tools and technologies to the pharma and biotech markets, including work with Bio-Rad, Sigma-Aldrich, BioScale and Molecular Devices.
The appointments strengthen Domainex’s commitment to bring its cutting-edge and highly effective drug discovery services to a rapidly increasing number of clients across North America.
Domainex Chief Operating Officer, Tom Mander, commented: “We’re delighted to have attracted Michael and Josephine, with their successful track records, to join Domainex and to announce the opening of our first overseas offices."
"Domainex has already established deep relationships and provided novel solutions to big pharma, emerging biotech and patient foundations in the US. These strategic appointments will allow us to take our powerful drug discovery capabilities to a broader client base in North America.”
Trevor Perrior, Chief Scientific Officer, added: “Locating our new business development operations in the San Diego and Boston bioclusters was the natural choice as they both mirror the innovative environment we already enjoy from our Medicines Discovery Centre in Europe’s leading biocluster at Cambridge, UK."
"We intend to work with pioneering life science organisations there and elsewhere, through our local representatives, to provide them maximum value for their R&D investment in accessing our multidisciplinary expertise.”
